We have begun the development of an antibody against a specific target validated in pancreatic cancer.

CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies.

CancerAppy closed 2021 with €690K total raised.

Together with our collaborators, we have found a new therapeutic target for TNBCs that we are currently patenting.

The Ministry of Science and Technology has granted Torres Quevedo research grant for our researcher Elisa Poyatos.

CancerAppy raised a pre-seed round of € 50K

Enisa has granted us a loan of 100K

CancerAppy has been selected to participate in the Spanish delegation of the 4YFN 2021 event

We released GeneReport 1.0

Cancerappy obtained the positive resolution of the Neotec 2020 program.

CancerAppy was one of the 24 projects selected to exhibit at the B-venture 2020 Bilbao.

Version 6.0 AI 1.0

AI + Drug Interaction / Personalized Medicine

Version 5.0

Code rewritten. Drug Interaction

CancerAppy raised a pre-seed round of € 120K

Version 4.0

Tested at 6 hospitals and universities

Cancerappy is founded in Bilbao as a startup